drugs & pharma

Pfizer is sinking billions in profits from COVID-19 into developing and marketing potential new treatment blockbusters for conditions like migraines, sickle cell disease and obesity.

FDA's accelerated reviews employ hotly debated effectiveness standards and result in drugs that are costly and of marginal benefit.